Regulation - Forest Laboratories

Filter

Current filters:

Forest Laboratories

Popular Filters

Actavis and Forest to divest four generics to gain FTC OK for merger

01-07-2014

In order for Ireland-headquartered generics major Actavis to complete its previously-announced $25 billion…

ActavisForest LaboratoriesGeneric pharmaceuticalsGenericsHealth Medical PharmaMedicinePharmaceutical industryPharmacologyRegulationUSA

Adamas Pharma gets $25 million milestone from Forest Labs

21-05-2014

Adamas Pharmaceuticals says it has received a $25 million milestone payment from Forest Laboratories…

Adamas PharmaceuticalsFinancialForest LaboratoriesMDX-8704NeurologicalPharmaceuticalRegulationUSA

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

moksha8 files Viibryd and Colobreathe in Brazil; amends Forest alliance

06-01-2014

Brazil-based pharma firm moksha8 has filed applications with the Brazilian regulatory authority, ANVISA,…

BrazilColoBreatheForest LaboratoriesLicensingMerck SeronoMoksha8NeurologicalPharmaceuticalRare diseasesRegulationSouth AmericaViibryd

FDA calls for more info from Forest and Gedeon Richter on cariprazine

21-11-2013

The US Food and Drug Administration has issued a complete response letter regarding the New Drug Application…

cariprazineForest LaboratoriesGedeon RichterNeurologicalNorth AmericaPharmaceuticalRegulation

Forest Labs and Almirall opt to delay US filing for combo COPD drug

15-08-2013

USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Forest Labs and Fabre's MMD drug gains FDA approval

26-07-2013

US drugmaker Forest Laboratories (NYSE: FRX) and France-based independent Pierre Fabre Laboratories have…

FetzimaForest LaboratorieslevomilnacipranNeurologicalNorth AmericaPharmaceuticalPierre FabreRegulation

NICE "green light" for Novartis' Tobi Podhaler and Forest's Colobreathe

24-01-2013

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in a final draft…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisPharmaceuticalPricingRare diseasesRegulationTobi Podhaler

FDA nod for use of Ironwood and Forest's Linzess in certain cases of IBS and constipation

03-09-2012

The US Food and Drug Administration last week approved Linzess (linaclotide), co-marketed by US drugmakers…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideLinzessNorth AmericaPharmaceuticalRegulation

US FDA backs Forest and Almirall's Tudorza Pressair to treat COPD

24-07-2012

US drugmaker Forest Laboratories (NYSE: FRX) and Spain's largest pharma firm Almirall (ALM: MC,) which…

AlmirallForest LaboratoriesNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

FDA extends review of Ironwood and Forest's linaclotide to September

24-04-2012

The US Food and Drug Administration has told USA-based drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD)…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulation

US FDA delays approval of Almirall and Forest Laboratories' COPD drug

30-03-2012

The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Forest Labs get EU appro for Colobreathe

27-02-2012

US drugmaker Forest Laboratories (NYSE: FRX) said on Friday that the European Medicines Agency has approved…

ColoBreatheColomycinEuropeForest LaboratoriesPharmaceuticalRare diseasesRegulation

US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall

24-10-2011

US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) said yesterday…

AlmirallForest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulationResearch

Back to top